- Home
- PLRX vs CHRS Comparison
PLRX vs CHRS Comparison
Compare PLRX & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLRX
- CHRS
- Stock Information
- Founded
- PLRX 2015
- CHRS 2010
- Country
- PLRX United States
- CHRS United States
- Employees
- PLRX N/A
- CHRS N/A
- Industry
- PLRX Biotechnology: Pharmaceutical Preparations
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PLRX Health Care
- CHRS Health Care
- Exchange
- PLRX Nasdaq
- CHRS Nasdaq
- Market Cap
- PLRX 87.0M
- CHRS 96.9M
- IPO Year
- PLRX 2020
- CHRS 2014
- Fundamental
- Price
- PLRX $1.46
- CHRS $1.12
- Analyst Decision
- PLRX Hold
- CHRS Strong Buy
- Analyst Count
- PLRX 10
- CHRS 4
- Target Price
- PLRX $9.79
- CHRS $5.38
- AVG Volume (30 Days)
- PLRX 1.4M
- CHRS 2.0M
- Earning Date
- PLRX 05-05-2025
- CHRS 05-08-2025
- Dividend Yield
- PLRX N/A
- CHRS N/A
- EPS Growth
- PLRX N/A
- CHRS N/A
- EPS
- PLRX N/A
- CHRS 0.25
- Revenue
- PLRX N/A
- CHRS $266,959,999.00
- Revenue This Year
- PLRX N/A
- CHRS N/A
- Revenue Next Year
- PLRX N/A
- CHRS $9.02
- P/E Ratio
- PLRX N/A
- CHRS $4.50
- Revenue Growth
- PLRX N/A
- CHRS 3.78
- 52 Week Low
- PLRX $1.10
- CHRS $0.66
- 52 Week High
- PLRX $16.52
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- PLRX 37.18
- CHRS 61.92
- Support Level
- PLRX $1.10
- CHRS $0.72
- Resistance Level
- PLRX $1.34
- CHRS $1.07
- Average True Range (ATR)
- PLRX 0.12
- CHRS 0.10
- MACD
- PLRX 0.15
- CHRS 0.04
- Stochastic Oscillator
- PLRX 88.45
- CHRS 95.19
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.